Hossein Borghaei is a native of Iran. He moved to the US as a student when he was 17 years old on his own due to the unstable political environment there after the revolution. He gradually helped his brothers, and eventually, his parents came to the US. He took on odd jobs and did what was needed to stay in school and eventually became a permanent resident and now a US citizen. After medical school and residency, Dr. Borghaei joined the fellowship training program at Fox Chase Cancer Center, where he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer.
In addition to clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is heavily involved in a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs with the aim of bringing these approaches to the clinic. He has a history of federal funding for some of his research activities. He was the Co-PI of the successful 8-year Pan-Canadian Early Detection of Lung Cancer Study involving eight centers across Canada from coast to coast with several high-impact publications such as the PanCan lung nodule malignancy risk prediction model that is currently used in the BC Lung Screening Program and recommended for use in certain settings by the British Thoracic Society and the American College of Radiology.
In a prospective head-to-head comparison, the International Lung Screening Trial team showed that the PLCOm risk prediction tool has significantly better sensitivity and positive predictive value than the USPSTF lung cancer screening eligibility criteria. He has published over scientific papers. Christian Rolfo, MD, Ph. Rolfo's clinical and research focus is on drug development, lung cancer, and other thoracic malignancies, biomarkers, resistant mechanisms discovery, and liquid biopsies.
Rolfo is actively working on drug development and lung cancer and mesothelioma treatment. His research is focused on molecular oncology, targeted therapies, and Immunotherapy using new techniques in liquid biopsies, specifically in extracellular vesicles and circulating free tumor DNA. Rolfo has authored more than scientific articles, has made several contributions to book chapters, and has served as a book editor.
He obtained his medical doctorate degree in Universidad Austral, Valdivia, Chile , and completed a surgical pathology training in Catholic University, Santiago, Chile Adi Gazdar and John Minna His major research interest is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer and the development of predictive biomarkers for targeted and immune-oncology therapies.
